LIRAGLUTIDE | A215503 | HIKMA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novo Nordisk Inc. et al v. Hikma Pharmaceuticals USA Inc. 4 patentsANDA 215503Liraglutide | D. Del. | 2021-12-21 | Terminated 2023-01-17 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$37.92
per ml
Lowest NADAC/Unit
$33.42
per ml
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00143914402LIRAGLUTIDE 2-PAK 18 MG/3 ML | $37.92 | ML | Generic | — | 2026-06-17 |
| 00143914403LIRAGLUTIDE 3-PAK 18 MG/3 ML | $33.42 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.